EFFECT OF SANDIMMUNE VS NEORAL CSA IN RENAL TRANSPLANT PATIENTS

SANDIMUNE 与 NEORAL CSA 对肾移植患者的影响

• 批准号: 6279179
• 负责人: ROBERT W STEINER
• 金额: $ 1.43万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6279179
• 关键词: clinical research; creatinine; cyclosporines; dosage forms; emulsions; human subject; human therapy evaluation; immunopharmacology; immunotherapy; kidney transplantation; transplantation immunology

Stable renal transplant patients will be converted from sandimmune to neoral at initial dose 1:1 to keep trough level normal and to assess effects on cyclosporine requirement and creatinine levels.

稳定的肾移植患者将从桑德免疫转变为 neoral 初始剂量 1:1 以保持谷值正常并评估 对环孢素需求和肌酐水平的影响。